Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.27.546784Source: DataRank Database

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2023). On theSindex it has a DataRank of 0.558. It has been cited 12 times, with 9 citing works in its 1-hop citation network.

N/A

0.558DataRank · unranked

Scored on demand from live citation data

Open Access12 citations · 9 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (28)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 69%Citation Network 31%

Base Score Contribution

0.385

From this paper's citation signal

Citation Network Contribution

0.173

From 7 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 9 citers.

Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs
Antiviral Research202312 citations30 referencesContributes 0.085
Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2
ACS Infectious Diseases20247 citations58 referencesContributes 0.036
A Novel HPLC-MS/MS Method for the Intracellular Quantification of the Active Triphosphate Metabolite of Remdesivir: GS-443902
Journal of Xenobiotics20252 citations35 referencesContributes 0.031
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Clinical Infectious Diseases202317 citations100 referencesContributes 0.029
COVID-19 therapeutics
Clinical Microbiology Reviews202441 citations376 referencesContributes 0.010

Authors (30)

Fernando R. Moreira ORCID,Mark R. Zweigart ORCID,Kendra L. Gully ORCID,Gabriela De la Cruz ORCID,Ariane J. Brown

Live enrichment

PubMed:37425890 OpenAlex:https://openalex.org/W4382362676

NIAID NIH HHS

Grant: R01 AI132178

NIAID NIH HHS

Grant: U19 AI109680

NIAID NIH HHS

Grant: U19 AI142759

NIAID NIH HHS

Grant: U19 AI171292

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2023/06/28/2023.06.27.546784.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2023.06.27.546784

repositoryhttps://doi.org/10.1101/2023.06.27.546784

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37425890

Fields of Study

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyViral Infections and Immunology Research

Keywords

VirologyCoronavirusCoronaviridaePandemicBiologyVirusNucleosideAntiviral drugIn vivoProdrugImmunologyMedicineDiseaseCoronavirus disease 2019 (COVID-19)PharmacologyInfectious disease (medical specialty)AntiviralsGS-5245Paxlovid™broad-spectrum drugsnirmatrelvirobeldesiviroral antiviral drugspandemic preparednessremdesivir

Sustainable Development Goals

SDG 0: Good health and well-being